Background:

RCM-1 is a FOXM1 inhibitor.

RCM-1 inhibits cellular proliferation via increasing duration of cell cycle and mitosis in human and mouse cancer cell lines in vitro. Treatment with RCM-1 increases duration of mitosis and cell cycle in the cancer cell lines. RCM-1 inhibits colony formation of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits migration of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the initiation as well as growth of cancer cell colonies in vitro[1].

RCM-1 treatment reduces growth of Rd76-9 rhabdomyosarcomas in mice. RCM-1 treatment decreases tumor cell proliferation and increases apoptosis in Rd76-9 rhabdomyosarcoma tumors. The RCM-1-treated Rd76-9 tumors show reduced FOXM1 staining and decreased expression of proliferation-specific markers Ki67 and PH3. Cleaved caspase staining is increased in the RCM-1 treated tumors, indicating an increase in apoptosis. RCM-1 treatment reduces growth of the B16-FlO melanoma tumors in mice. RCM-1 decreases the B 16-FlO tumor growth as compared to the Vehicle -treated group. RCM-1 treatment decreases tumor cell proliferation and increased apoptosis in B16-FlO melanoma tumors. RCM-1 treatment reduces growth of the human H2122 lung adenocarcinoma in mice[1].

[1]. ARYL SULFONOHYDRAZIDES.WO2018057550A1.